The Virtual CTSA Visiting Scholar Program to Support Early-Stage Clinical and Translational Researchers: Implementation and Outcomes

1M.A. Bredella is professor of radiology; vice chair, Department of Radiology, Massachusetts General Hospital; and director, KL2/Catalyst Medical Research Investigator Training Program, Harvard Catalyst, The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, Massachusetts.

2D.M. Rubio is professor of medicine, biostatistics, bioinformatics, and clinical and translational science; assistant vice chancellor for clinical research education and training, Health Sciences; director, Institute for Clinical Research Education; and director, KL2, Team Science, and Workforce Development, Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.

3J. Attia is health project coordinator, Center for Leading Innovation and Collaboration, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York.

4T.H. Kelly is Robert Straus Professor and chair, Department of Behavioral Science, College of Medicine; associate dean for research and PhD faculty affairs, College of Nursing; and director, KL2 and Workforce Development, Center for Clinical and Translational Science; University of Kentucky, Lexington, Kentucky.

5S. McIntosh is associate professor; and survey team faculty lead, Center for Leading Innovation and Collaboration, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York.

6E.A. Meagher is professor of medicine and pharmacology; director, Translational Research Education, Institute for Translational Medicine and Therapeutics; and vice dean, Clinical Research Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

7S. Pusek is director, Education Programs, North Carolina TraCS Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

8M. Rubio is program director, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland.

9J. Tsevat is professor of medicine; Joaquin G. Cigarroa, Jr., MD, Distinguished Chair; director, ReACH Center; director, KL2 Program, University of Texas Health Science Center at San Antonio; and professor of population health, Dell Medical School, University of Texas at Austin; and Institute for the Integration of Medicine and Science, Center for Research to Advance Community Health, Department of Medicine, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

10J.G. Umans is KL2 program director, Georgetown–Howard Universities Center for Clinical and Translational Science; associate professor of medicine and of obstetrics and gynecology, Georgetown University, Washington, DC; scientific director, Biomarker, Biochemistry and Biorepository Core; and scientific director, Field Studies Division, MedStar Health Research Institute, Hyattsville, Maryland.

The authors have informed the journal that they agree that Miriam A. Bredella and Doris M. Rubio have completed the intellectual and other work typical of the first author.

Funding/Support: This work was funded in part by the University of Rochester Center for Leading Innovation and Collaboration (CLIC) and the Clinical and Translational Science Award (CTSA) coordinating center, funded by the National Center for Advancing Translational Sciences (NCATS) (award #U24TR002260). From CLIC the authors wish to thank Laura Hassinger, Abby Williams, Julie Schwan, and Rebecca Laird for assistance with survey design, implementation, and data management. This work was also supported in part by the National Institutes of Health NCATS through these grant award numbers: KL2TR002542 (Bredella); UL1TR001998 and KL2TR001996 (Kelly); UL1TR001878, TL1TR001880, and KL2TR001879 (Meagher); UL1TR002489 (Pusek); KL2TR001856 (Rubio); KL2TR002646 (Tsevat); KL2TR001432 and UL1TR001409 (Umans).

Ethical approval: The survey project was reviewed by the University of Rochester Institutional Review Board and determined to be exempt as defined by title 45 of the Code of Federal Regulations Part 46.

Other disclosures: None reported.

Disclaimers: This work is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NCATS, or CLIC.

Correspondence should be addressed to Doris Rubio, University of Pittsburgh, 200 Meyran Ave, Suite 200, Pittsburgh, PA 15213; email: [email protected].

留言 (0)

沒有登入
gif